Balancing Blood Sugar, Weight and Beyond

Presented by: Christine Gee

April 3, 2024

GLP-1 agonists are heavily publicized in the news. During this presentation, we will look at the prevalence and economic burden of type 2 diabetes and obesity and how GLP-1 agonists are a treatment alternative for these conditions. The effectiveness of GLP-1 agonists along with cost implications will be discussed. While GLP-1 agonists are effective therapies, these medications are only one facet to the multi-disciplinary approach to type 2 diabetes and weight management; thus, we will look at other factors that should be considered as employers look to decide whether to cover GLP-1 agonists for weight management.

About our Speaker:

Christine Gee is a Senior Clinical Pharmacist who recently joined Premera. Over her professional career expanding 25 years, she has gained valuable experience working in a variety of roles, including retail, hospital, and clinical pharmacy; health plan; and pharmacy benefit management. Christine has a broad range of knowledge including accreditation; formulary development and management; prior authorization/utilization management programs; and pharmacy benefit plan administration. She is passionate about developing innovative solutions to improve the overall healthcare experience. Outside of work, she enjoys photography and spending time with her family.

Take Aways

1. How GLP-1 agonists work for type 2 diabetes and weight management.
2. Future pipeline of GLP-1 agonists
3. GLP-1 agonists growth in popularity and utilization trends 

This meeting is sponsored by: